Previous close | 2,103.55 |
Open | 2,105.00 |
Bid | 2,086.90 x 0 |
Ask | 2,095.50 x 0 |
Day's range | 2,078.40 - 2,144.55 |
52-week range | 1,243.15 - 2,649.95 |
Volume | |
Avg. volume | 9,798 |
Market cap | 356.354B |
Beta (5Y monthly) | 0.22 |
PE ratio (TTM) | 67.11 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 32.00 (1.53%) |
Ex-dividend date | 30 Jun 2023 |
1y target est | N/A |
Wednesday, GSK Plc (NYSE:GSK) reported first-quarter sales of $9.33 billion (7.4 billion Sterling Pounds), up 10% Y/Y and 13% excluding COVID. Vaccines’ sales increased 16% at constant currency to 2.28 billion Pounds, reflecting U.S. demand for Arexvy and strong market growth for Shingrix in International and European markets. Shingrix sales reached 945 million Pounds, up 18% at constant currency, with Arexvy sales of 182 million Pounds. Specialty Medicine sales increased 17% to 2.5 billion poun
Glaxo (GSK) delivered earnings and revenue surprises of 15.96% and 3.99%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
In this article, we will be taking a look at the 20 fastest growing health tech companies in the world. If you do not want to learn about the trends in digital health market, head straight to the 5 Fastest Growing Health tech Companies in the World. Explosive Growth and Key Trends in the Digital […]